Charts

News

28 Mar, 2024
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing.
26 Mar, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.43 per unit.
25 Mar, 2024
During the last three months, 25 analysts shared their evaluations of ACADIA Pharmaceuticals (NASDAQ:ACAD), revealing diverse outlooks ...
22 Mar, 2024
Symbols mentioned in this story: LABU, FDMT, ETNB, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
19 Mar, 2024
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...
15 Mar, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
14 Mar, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. The post 3 Pharma Stocks to Sell in March Before They Crash & Burn appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
13 Mar, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.
12 Mar, 2024
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported ...
14:46
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday! The post Why Are Airline Stocks Down Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin. The post Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
Gainers Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's ...
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Monday,Acadia Pharmaceuticals Inc(NASDAQ:ACAD) released top-line results from the Phase 3 ADVANCE-2 trial evaluating ...
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA ...
11 Mar, 2024
Gainers CareMax (NASDAQ:CMAX) stock increased by 16.9% to $8.0 during Monday's after-market session. The market value of their ...
Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative symptoms of schizophrenia in a late-stage study. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the treatment of psychosis related to dementia and Alzheimer's disease in 2021 and 2022, respectively. In the current study that involved 454 adult patients, pimavanserin did not outperform a placebo in reducing negative symptoms of schizophrenia, including poor socialization and lack of motivation, Acadia said.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
08 Mar, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. The post 3 Stock Winners That Are Up 1,000% or More in 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
01 Mar, 2024
Shareholders might have noticed that ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) filed its annual result this time last...
29 Feb, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript February 27, 2024 ACADIA Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.28 EPS, expectations were $0.32. ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
ACADIA Pharmaceuticals ( NASDAQ:ACAD ) Full Year 2023 Results Key Financial Results Revenue: US$726.4m (up 40% from FY...
28 Feb, 2024
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CryoPort Inc (CYRX), where a total of 3,007 contracts have traded so far, representing approximately 300,700 underlying shares. That amounts to about 89.7% of CYRX's average daily trading volume over the past month of 335,370 shares..
Acadia stock plunged Wednesday after the company issued light guidance for Daybue. ACAD stock undercut its 50-day line.
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
In the preceding three months, 13 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD), presenting a wide array of ...
27 Feb, 2024
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ACADIA's DAYBUE Launch Drives 40% Annual Revenue Increase
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM. Here's what investors ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on ...
26 Feb, 2024
25 Feb, 2024
We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) business as it appears the...
20 Feb, 2024
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
13 Feb, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
08 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. The post The 3 Most Undervalued Biotech Stocks to Buy in February 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
31 Jan, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transition period, Austin D. Kim, Executive Vice President, General Counsel and Secretary will be leaving Acadia to pursue other opportunities.
24 Jan, 2024
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 12 analysts in the last three months, revealing a diverse range of ...
23 Jan, 2024
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the April 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 87 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
22 Jan, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.61 per unit.
18 Jan, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness.
10 Jan, 2024
Symbols mentioned in this story: XBI, KRTX, ACAD, MRNA Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
29 Dec, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...
Analysts' ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the last quarter vary from bullish to bearish, as provided by 13 ...
21 Dec, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session.
14 Dec, 2023
It’s been a complicated year for tech firms outside those “Magnificent Seven” names that have, to some degree, outgrown a simple “tech” distinction. High interest rates have taken a toll on tech firms. That includes biotech firms that rely on borrowing in early stages before they can have patents approved. Despite that, however, at least [...] The post Biotech ETF SBIO Sees Buy Signal Amid Hot Returns appeared first on ETF Trends.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s Order, the Court ruled in favor of Acadia on all of the disputed claim construction points.
13 Dec, 2023
Acadia notched a win in a patent battle Wednesday pertaining to its Parkinson's drug and ACAD stock soared to a four-month high.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Boeing Co. (BA), where a total of 70,881 contracts have traded so far, representing approximately 7.1 million underlying shares..
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The court ruled in favor of Acadia on all grounds. The ruling came in Acadia’s litigation against MSN Laboratories Pvt. Ltd., MSN Pharmaceuticals, Inc. and other ANDA (Abbreviated New Drug Application) filers and concludes this litigation in the District Court.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company wonsummary judgement in a patent ...
Gainers Shattuck Labs (NASDAQ:STTK) stock moved upwards by 93.8% to $4.09 during Wednesday's regular session. The company's market cap ...
17:00
FinancialContent
In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 2.2% on the day. Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 30.4% and shares of Vertex Pharmaceuticals, up about 9.3% on the day.
12 Dec, 2023
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Bullish Somewhat ...
06 Nov, 2023
01 Nov, 2023

Related Articles